On the recordFebruary 3, 2016
I cannot overstate the importance of treating each biosimilar individually rather than as if they were a generic drug.
Source
congress.govEditor's note · Context
Barton emphasizes the need for individual assessment of biosimilars.
Share & report
More from Joe Barton
Jun 22, 2018
Mr. Chairman, we have a great piece of legislation before us today. Chairman Walden and Ranking Member Pallone have been great leaders in shepherding dozens of opioid-related bills through the Energy and Commerce Committee. This particular…
Jul 16, 2018
It is always good to have hearings like this to try to, through bipartisan basis, get facts on the table.
Jul 16, 2018
Well, then the manufacturer doesn't have to give the coupon. If they don't give the coupon to the doctor, the doctor doesn't give it to the patient.
Other voices in this conversation
